ChengDa Pharmaceuticals Co. Ltd. (301201) — Working Capital to Net Assets Ratio
ChengDa Pharmaceuticals Co. Ltd. (301201) has a Working Capital to Net Assets ratio of 53.7% as of March 2026. Working capital of CN¥1.13 Billion (current assets of CN¥1.30 Billion minus current liabilities of CN¥171.77 Million) is measured against net assets of CN¥2.10 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See ChengDa Pharmaceuticals Co. Ltd. (301201) defensive interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
ChengDa Pharmaceuticals Co. Ltd. Working Capital to Net Assets (2019–2025)
This chart shows how ChengDa Pharmaceuticals Co. Ltd.'s Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the ratio stands at 53.7%, reflecting working capital of CN¥1.13 Billion against net assets of CN¥2.10 Billion CNY. For the complete balance sheet picture, see how large is ChengDa Pharmaceuticals Co. Ltd.'s balance sheet.
Annual Working Capital to Net Assets for ChengDa Pharmaceuticals Co. Ltd. (2019–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check ChengDa Pharmaceuticals Co. Ltd. (301201) asset resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 52.5% | CN¥1.10 Billion | CN¥2.10 Billion | CN¥1.30 Billion | CN¥202.97 Million | ▼ -3.8 pp |
| 2024 | 56.3% | CN¥1.21 Billion | CN¥2.15 Billion | CN¥1.42 Billion | CN¥206.76 Million | ▼ -8.2 pp |
| 2023 | 64.6% | CN¥1.47 Billion | CN¥2.28 Billion | CN¥1.64 Billion | CN¥171.53 Million | ▼ -6.7 pp |
| 2022 | 71.3% | CN¥1.58 Billion | CN¥2.22 Billion | CN¥1.68 Billion | CN¥99.54 Million | ▲ +56.6 pp |
| 2021 | 14.7% | CN¥78.15 Million | CN¥529.93 Million | CN¥225.93 Million | CN¥147.78 Million | ▼ -7.8 pp |
| 2020 | 22.6% | CN¥103.68 Million | CN¥458.91 Million | CN¥173.52 Million | CN¥69.84 Million | ▲ +11.1 pp |
| 2019 | 11.5% | CN¥41.22 Million | CN¥357.35 Million | CN¥227.55 Million | CN¥186.33 Million | — |